Background New treatment options and strategies have dramatically reduced the severity and impact of rheumatoid arthritis (RA) and especially early intensive combination therapy, aimed at achieving remission, has shown good clinical outcomes. The reason for early identification and treatment of RA is to control progression of the disease. Since there is no cure for RA, the current most important goal is to reach remission as soon as possible, which should be sustained during the course of the disease.
Objectives Despite wide implementation of treat-to-target (T2T) strategies in RA, a proportion of patients still fail to achieve early remission. This study aimed to identify baseline predictors of reaching remission in Dutch patients with early RA following a T2T strategy.
Methods Baseline demographic, clinical and patient-reported outcome measures and one-year follow-up data were used from patients with early RA included in the DREAM remission induction cohort II study. Survival analyses and simple and multivariable logistic regression analyses were used to examine remission rates and significant predictors of achieving remission.
Results A total number of 137 patients was included. 77.2% of the patients reached remission at least once in 12 months follow-up, and median time to first remission was 17 weeks. None of the examined baseline variables were significantly associated with achieving remission within 1 year. Lower ESR (p=0.007), male gender (p=0.057), better physical health status (p=0.062) and fewer tender joints (p=0.175) were significantly or marginally associated with achieving remission within 17 weeks. In multivariable analysis, however, only ESR remained significantly predictive (p=0.023).
Conclusions The results indicate that baseline characteristics were not predictive of early remission. Together with the high proportion of responders, this provides additional evidence for the general applicability of T2T strategies in patients with early RA.
Disclosure of Interest None declared